Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

398
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
398
Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

864
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
864
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

275
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
275
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

478
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
478
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

304
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
304
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

434
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
434

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of Microbiota Restoration Therapies for Recurrent Clostridioides difficile Infection.

The American journal of gastroenterology·2026
Same author

When Does Clostridioides difficile "Recur"? Reconcile Epidemiologic & Bedside Recurrent CDI definitions.

The Journal of infectious diseases·2026
Same author

Clostridioides difficile infection in inflammatory bowel disease: an observational study in flares of ulcerative colitis and a South Asian region-specific systematic review and meta-analysis.

Therapeutic advances in gastroenterology·2026
Same author

Responsible use of large language models in gastroenterology and hepatology.

Therapeutic advances in gastroenterology·2026
Same author

Fecal microbiota transplantation in chronic liver disease: Current and future state of the art.

Hepatology communications·2026
Same author

Patient-reported benefits of colonoscopicallyadministered microbiota restoration therapy: a qualitative study of adult patients with recurrent <i>Clostridioides difficile</i> infection.

Therapeutic advances in gastroenterology·2026

Related Experiment Video

Updated: Nov 9, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K

Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!

S Khanna1

  • 1From the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

Journal of Internal Medicine
|April 15, 2021
PubMed
Summary

Clostridioides difficile infection (CDI) management is challenging due to high recurrence rates. Microbiota restoration therapies, especially standardized fecal microbiota transplantation, offer over 90% recurrence prevention, surpassing antibiotics.

Keywords:
Clostridioides difficiledysbiosisfaecal microbiota transplantationinfectionmicrobiomemicrobiotarecurrence

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.2K

Related Experiment Videos

Last Updated: Nov 9, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.1K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.2K

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Microbiology

Background:

  • Clostridioides difficile infection (CDI) is a common healthcare-associated infection with significant recurrence rates, posing a clinical challenge.
  • Current diagnostic methods like PCR may lead to false positives, necessitating refined testing strategies.
  • Recurrent CDI significantly impacts patient health, with recurrence rates reaching 60% after multiple infections.

Purpose of the Study:

  • To review current management and diagnostic principles for CDI.
  • To summarize emerging and existing data on fecal microbiota transplantation (FMT) for CDI.
  • To focus on standardized microbiota restoration therapies (SMTRs) for preventing CDI recurrence.

Main Methods:

  • Review of existing literature on CDI diagnosis and treatment.
  • Analysis of data from clinical trials on FMT and SMTRs.
  • Comparison of recurrence prevention rates between microbiota restoration and antibiotic therapies.

Main Results:

  • Microbiota restoration therapies demonstrate over 90% success in preventing CDI recurrence, significantly higher than antibiotic treatments (<50%).
  • Standardized microbiota restoration therapies in capsule and enema forms show promising results in clinical trials (e.g., SER-109, RBX2660).
  • Fecal microbiota transplantation, while effective, faces challenges with heterogeneity and adverse events, driving the development of standardized alternatives.

Conclusions:

  • Standardized microbiota restoration therapies represent a highly effective strategy for managing recurrent CDI.
  • Emerging standardized therapies offer improved safety and efficacy profiles compared to traditional FMT.
  • Refined diagnostic approaches and advanced microbiota restoration therapies are crucial for addressing the CDI challenge.